Patient Perspectives and Experiences with Psilocybin Treatment for Treatment-Resistant Depression: a Qualitative Study

Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study

Psilocybin is the most researched classic psychedelic for Treatment-Resistant Depression (TRD). While optimizing set and setting are considered essential for efficacy and safety, patient perspectives on these aspects have rarely been investigated. To address this knowledge gap, the current paper explored the experiences of 11 TRD patients (8 women, 3 men) participating in a double-blind randomized clinical trial with a single session of oral (1,…

Hope for Depression and Other Diagnoses with Psychedelics

Research on synthetic psychedelics progresses, and there's hope to prove psilocybin safe and effective in intractable depression. The HHS and FDA voice support for psychedelics.

“Liberation in Order to Heal”—Psychedelics Movement at Crossroads

In June, the world’s largest psychedelics conference returned to Denver. Eight thousand participants gathered to hear 500 presenters over the course of a week. Psychedelic Science, organized by the Multidisciplinary Association for Psychedelic Studies (MAPS),  brought together people from 50 countries. They discussed such diverse topics as decriminalization initiatives, therapeutic and commercial regulation, electronic music raves, artificial in…

Fascinating new advances in psychedelic science reveal how they may heal the mind

New studies are revealing how psychedelics interact with neural circuits, receptor systems, and psychological processes in ways that may support lasting mental health improvements. By combining brain imaging, behavioral testing, and molecular tools, researchers are beginning to isolate the pathways through which these substances influence mood, cognition, and self-perception. These findings mark a shift from anecdotal and early-phase trials towa…